Use of Eye Tracking to Study Social Perception Abnormalities in Children with Angelman Syndrome
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Dec 12, 2024
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how eye tracking can help researchers understand social perception issues in children with Angelman syndrome, a rare genetic disorder that affects how children develop and communicate. The goal is to see if eye tracking, which involves measuring where and how long a person looks at different things, can identify specific social behavior challenges in children with Angelman syndrome. If successful, these findings could lead to new ways to evaluate treatments for this condition.
The study is looking for 40 children aged 3 to 17 who have been diagnosed with Angelman syndrome, as well as 20 healthy children of the same age to serve as a comparison group. To participate, children must have parental consent and must be willing to take part in the research. Participants will likely engage in activities that involve looking at different images or videos while their eye movements are tracked. This could help improve our understanding of how children with Angelman syndrome perceive social situations and could pave the way for better therapies in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 40 children with Angelman syndrome diagnosed by genetic assessment or EEG.
- • 20 healthy volunteer control children with no known genetic or psychiatric neurological pathology.
- • Aged between 3 - 17 years.
- • Male or female.
- • Holders of parental authority and minors informed and not opposed to participation in the research.
- Exclusion Criteria:
- • Refusal to participate in the study.
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Nathalie MD, PhD Boddaert
Study Director
Assistance Publique - Hôpitaux de Paris
Monica MD Zilbovicius
Study Director
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported